News
Specialists are debating the best approach in cardiogenic shock after a new analysis of data comparing Impella with ...
Patients who undergo catheter ablation for atrial fibrillation (AFib) who also have heart failure with preserved ejection fraction (HFpEF) experienced a greater benefit from ablation in terms of ...
Hosted on MSN20d
Johnson & Johnson (NYSE:JNJ) Q1 2025 Earnings Call TranscriptThese included updates to the American College of Cardiology and American Heart Association guidelines for our Impella heart pump, which based on evidence from the DANGER shock trial was upgraded ...
In patients undergoing high‐risk percutaneous coronary intervention, Impella has become an important adjunctive tool to support revascularization. The impact of age on the outcomes of patients ...
Femoral neuropathy, also called femoral nerve dysfunction, is one possible cause of movement and sensation problems in the legs. Femoral neuropathy occurs when something affects the femoral nerve ...
Edwards said in a news release that delivery of both the dock and valve takes place through a percutaneous, 29F outer diameter steerable guide sheath inserted through the femoral vein. Irvine ...
There has been a notable increase over the last decade in the volume of outpatient, inpatient, and advanced therapy needs associated with patients with heart failure (HF), according to a new report ...
March 27, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella ® heart pump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results